WHO ICTRP trial
Immunotherapy combined with hypofractionated SBRT, antivascular targeting and…
ChiCTR2300076572 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300076572 |
|---|---|
| Public title | Immunotherapy combined with hypofractionated SBRT , antivascular targeting and low-dose chemotherapy for the first-line treatment of non-sensitive gene mutant advanced NSCLC:An exploratory clinical study |
| Scientific title | Immunotherapy combined with hypofractionated SBRT , antivascular targeting and low-dose chemotherapy for the first-line treatment of non-sensitive gene mutant advanced NSCLC:An exploratory clinical study |
| Primary sponsor | Fuzhou Pulmonary Hospital of fujian |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Non-small cell lung cancer |
| Interventions | Experiment group:SBRT,Toripalimab,Anlotinib,Albumin bound paclitaxel,probiotics,traditional Chinese medicine,GM-CSF |
| Registration date | Oct 12, 2023 |
| Target size | Experiment group:42 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: